OncoMatch/Clinical Trials/NCT05838716
Vitamin D for Prostate Endocrine Therapy
Is NCT05838716 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for stage i prostate cancer ajcc v8.
This phase III trial tests whether high-dose vitamin D works in treating androgen-deprivation therapy (ADT)-induced bone loss in patients with prostate cancer who are undergoing androgen-deprivation therapy. Vitamins are substances that the body needs to grow and develop normally. Vitamin D helps the body absorb calcium. Calcium is one of the main building blocks of bone. A lack of vitamin D can lead to bone diseases such as osteoporosis or rickets. This trial may help researchers determine if high-dose vitamin D helps keep bones strong, lowers number of falls, and lessens fatigue in men getting androgen-deprivation therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage I, II, III, IVA
Prior therapy
Must have received: LHRH agonist — starting or within past 6 months
Be starting ADT or have received their first ADT treatment in the past 6 months, with a total of at least 6 planned months of treatment (both luteinizing hormone-releasing hormone [LHRH] antagonists and LHRH agonists are permitted)
Must have received: LHRH antagonist — starting or within past 6 months
Be starting ADT or have received their first ADT treatment in the past 6 months, with a total of at least 6 planned months of treatment (both luteinizing hormone-releasing hormone [LHRH] antagonists and LHRH agonists are permitted)
Cannot have received: pharmacologic bone-modifying agent (oral bisphosphonates, intravenous bisphosphonates, denosumab, teriparatide)
Have long term (greater than 3 months) use of any pharmacologic bone-modifying agent including but not limited to oral or intravenous (IV) bisphosphonates, denosumab, or teriparatide prior to enrollment
Lab requirements
Kidney function
normal GFR (glomerular filtration rate > 30ml); exclusion: stage IV chronic kidney disease
Have a normal GFR (glomerular filtration rate > 30ml); Have a diagnosis of stage IV chronic kidney disease [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Helen F Graham Cancer Center · Newark, Delaware
- Medical Oncology Hematology Consultants PA · Newark, Delaware
- Carle at The Riverfront · Danville, Illinois
- Cancer Care Specialists of Illinois - Decatur · Decatur, Illinois
- Carle Physician Group-Effingham · Effingham, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify